Delphia Therapeutics

Delphia Therapeutics is a biopharmaceutical company developing cancer treatments based on a concept called "activation lethality." This approach targets the vulnerability of cancer cells to the over-activation of oncogenes, the genes that can cause cancer.

Instead of inhibiting cancer-driving pathways, the company's method involves selectively over-activating them to destroy the cancer cells. Delphia Therapeutics is advancing this new treatment paradigm to create a new generation of precision medicines. The company utilizes functional genomics, moving beyond traditional loss-of-function screening methods like CRISPR to explore gain-of-function approaches. This allows them to study the effects of over-activating specific cellular pathways.

The company operates in the oncology market, with its primary clients being cancer patients who could benefit from these novel therapies. Its business model is centered on the research and development of these new drugs. The company recently secured $67 million in a Series A funding round, which will likely be used to advance its drug candidates through preclinical and clinical development. Revenue generation will likely come from the eventual commercialization of its therapies, potentially through partnerships or licensing agreements with larger pharmaceutical companies.

Keywords: activation lethality, oncology, cancer therapeutics, precision medicine, biopharmaceutical, oncogenes, functional genomics, cancer treatment, drug development, biotechnology